ストックスクリーナーアプリを入手
29.60
0.54%
0.16
アフターアワーズ：
29.60
前日終値:
$29.44
開ける：
$29.8
24時間の取引高:
312.73K
Relative Volume:
0.58
時価総額：
$1.41B
収益：
-
当期純損益:
$-86.97M
株価収益率:
-12.24
EPS:
-2.4189
ネットキャッシュフロー:
$-81.88M
1週間 パフォーマンス:
+1.93%
1か月 パフォーマンス:
-10.28%
6か月 パフォーマンス:
+31.26%
1年 パフォーマンス:
+145.24%
1日の値動き範囲:
$28.82
$30.64
1週間の範囲:
$27.56
$32.03
52週間の値動き範囲:
$9.43
$44.89
Mbx Biosciences Inc Stock (MBX) Company Profile
Compare MBX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
29.60 | 1.40B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2025-12-04 | 開始されました | Goldman | Sell |
| 2025-11-04 | 開始されました | TD Cowen | Buy |
| 2025-10-15 | 開始されました | Truist | Buy |
| 2025-08-15 | 再開されました | Jefferies | Buy |
| 2025-08-05 | 開始されました | Mizuho | Outperform |
| 2025-07-16 | 開始されました | Oppenheimer | Outperform |
| 2025-04-10 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-10-08 | 開始されました | Guggenheim | Buy |
| 2024-10-08 | 開始されました | JP Morgan | Overweight |
| 2024-10-08 | 開始されました | Jefferies | Buy |
| 2024-10-08 | 開始されました | Stifel | Buy |
すべてを表示
Mbx Biosciences Inc (MBX) 最新ニュース
MBX Biosciences (NASDAQ: MBX) director awarded RSUs and 74,249 stock options - Stock Titan
MBX (MBX) Rule 144: Bartram sold 21,484 shares; Fidelity lists 5,000 - Stock Titan
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX), Cytokinetics (CYTK) and Crescent Biopharma (CBIO) - The Globe and Mail
MBX SEC FilingsMBX Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BlackRock (MBX) files Schedule 13G/A showing 4.8% ownership - Stock Titan
MBX Biosciences stock down on pricing upsized public offering at $18.00 per share - MSN
Wall Street Analysts See a 280.14% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? - MSN
A Look At MBX Biosciences (MBX) Valuation After Its Recent Share Price Move - Sahm
MBX Biosciences (NASDAQ:MBX) Amid Evolving Biotech Trends - Kalkine Media
MBX Biosciences (NASDAQ:MBX) Trading Down 6.3%Should You Sell? - MarketBeat
Truist reiterates Buy on MBX Biosciences stock ahead of trial data By Investing.com - Investing.com South Africa
Truist reiterates Buy on MBX Biosciences stock ahead of trial data - Investing.com Australia
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio - The Manila Times
MBX to detail obesity drug pipeline at May 11 online, in-person event - Stock Titan
MBX Biosciences Inc. beats EPS estimates by 20.4%Community Driven Stock Picks - Xã Châu Thành
MBX Biosciences (MBX) Stock Outlook | MBX Biosciences Inc. beats EPS estimates by 20.4%Dividend Growth - Xã Vĩnh Công
MBX Biosciences, Inc. ($MBX) CEO 2025 Pay Revealed - Quiver Quantitative
Proposed sale of 10,423 MBX shares (NASDAQ: MBX) reported - Stock Titan
Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share Purchase - The Motley Fool
Aaron Wealth Advisors Increases MBX Biosciences Stake to $37 Million - HarianBasis.co
[ARS] MBX Biosciences, Inc. SEC Filing - Stock Titan
MBX Biosciences (NASDAQ: MBX) plans 2026 virtual meeting and auditor vote - Stock Titan
MBX Biosciences (MBX) director receives capped 2025 stock option grant - Stock Titan
MBX Biosciences (MBX) grants 33,751 stock options to director Hoerter - Stock Titan
Aaron Wealth Advisors Increases Stake in MBX Biosciences - Intellectia AI
MBX Biosciences, Inc. (NASDAQ:MBX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
MBX Biosciences, Inc. (NASDAQ:MBX) Short Interest Up 20.4% in March - MarketBeat
Stifel reiterates Buy on MBX Biosciences stock, keeps $50 target By Investing.com - Investing.com Australia
Stifel reiterates Buy on MBX Biosciences stock, keeps $50 target - Investing.com
Is MBX Biosciences Inc stock influenced by commodity pricesWeekly Earnings Recap & Daily Growth Stock Tips - baoquankhu1.vn
Is MBX Biosciences (MBX) Stock cheap compared to earnings | Price at $31.64, Up 2.08%Fast Rising Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Goldman Sachs initiates coverage of MBX Biosciences (MBX) with sell recommendation - MSN
MBX Biosciences (NASDAQ:MBX) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
MBX Biosciences, Inc. focuses on science-led innovation to transform endocrine and metabolic disease treatment - Traders Union
MBX Biosciences (NASDAQ:MBX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Institution Moves: Is MBX Biosciences Inc part of any ETF2026 Sector Review & Technical Entry and Exit Tips - baoquankhu1.vn
Is MBX Biosciences (MBX) Stock Rebounding | Price at $31.30, Down 5.12%Trending Buy Opportunities - Cổng thông tin điện tử tỉnh Tây Ninh
Does MBX (MBX) Options-Driven Breakout Reveal Deeper Shifts In Its Investment Narrative? - Yahoo Finance
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
MBX Biosciences (MBX) Is Up 16.6% After Analyst Initiation And Leadership Award News Has The Bull Case Changed? - Sahm
MBX Biosciences Approves Equity-Based Inducement Grant for New Employee Under Nasdaq Rule - geneonline.com
MBX Biosciences Reports Inducement Grant - National Today
Lifesci Capital Weighs in on MBX Biosciences Q1 Earnings - MarketBeat
New MBX business chief gets 130,000 stock options at $32.29 - Stock Titan
MBX Biosciences (NASDAQ:MBX) Upgraded at Lifesci Capital - MarketBeat
Mbx Biosciences Inc (MBX) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):